Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 99 | 2024 | 21012 | 5.040 |
Why?
|
Peripheral Nervous System Diseases | 12 | 2024 | 710 | 3.660 |
Why?
|
Exercise | 48 | 2024 | 5884 | 3.540 |
Why?
|
Exercise Therapy | 22 | 2024 | 928 | 3.060 |
Why?
|
Survivors | 29 | 2022 | 2371 | 2.710 |
Why?
|
Acupuncture Therapy | 5 | 2024 | 486 | 2.400 |
Why?
|
Neoplasms | 49 | 2024 | 22164 | 2.330 |
Why?
|
Music Therapy | 4 | 2023 | 110 | 2.320 |
Why?
|
Aromatase Inhibitors | 13 | 2019 | 513 | 2.160 |
Why?
|
Yoga | 3 | 2022 | 281 | 1.770 |
Why?
|
Obesity | 33 | 2023 | 12938 | 1.750 |
Why?
|
Quality of Life | 40 | 2024 | 13361 | 1.550 |
Why?
|
Life Style | 21 | 2024 | 3914 | 1.460 |
Why?
|
Physical Fitness | 8 | 2019 | 739 | 1.340 |
Why?
|
Metformin | 14 | 2024 | 906 | 1.170 |
Why?
|
Antineoplastic Agents | 19 | 2024 | 13637 | 1.170 |
Why?
|
Weight Loss | 11 | 2022 | 2683 | 1.000 |
Why?
|
Mind-Body Therapies | 3 | 2023 | 279 | 1.000 |
Why?
|
Fatigue | 12 | 2024 | 1551 | 0.950 |
Why?
|
Health Behavior | 7 | 2024 | 2641 | 0.950 |
Why?
|
Hot Flashes | 2 | 2024 | 330 | 0.930 |
Why?
|
Body Weight | 10 | 2022 | 4618 | 0.910 |
Why?
|
Acupressure | 1 | 2023 | 16 | 0.880 |
Why?
|
Body Mass Index | 15 | 2023 | 12951 | 0.880 |
Why?
|
Receptors, Estrogen | 8 | 2024 | 2208 | 0.830 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.810 |
Why?
|
Medical Oncology | 10 | 2022 | 2321 | 0.780 |
Why?
|
Female | 126 | 2024 | 392581 | 0.740 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11740 | 0.740 |
Why?
|
Humans | 176 | 2024 | 761423 | 0.700 |
Why?
|
Mobility Limitation | 1 | 2024 | 408 | 0.690 |
Why?
|
Receptor, erbB-2 | 8 | 2022 | 2557 | 0.670 |
Why?
|
Diet | 12 | 2024 | 8074 | 0.640 |
Why?
|
Anxiety | 8 | 2023 | 4572 | 0.600 |
Why?
|
Telemedicine | 4 | 2023 | 3051 | 0.590 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2022 | 9277 | 0.560 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1728 | 0.550 |
Why?
|
Physical Endurance | 2 | 2009 | 366 | 0.520 |
Why?
|
Paclitaxel | 5 | 2024 | 1732 | 0.510 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1723 | 0.500 |
Why?
|
Tertiary Prevention | 1 | 2015 | 8 | 0.500 |
Why?
|
Estrogens | 2 | 2012 | 1522 | 0.500 |
Why?
|
Burnout, Professional | 1 | 2023 | 704 | 0.480 |
Why?
|
Arthralgia | 2 | 2019 | 461 | 0.480 |
Why?
|
Telephone | 3 | 2014 | 627 | 0.460 |
Why?
|
Disabled Persons | 1 | 2024 | 1225 | 0.460 |
Why?
|
Lymph Nodes | 2 | 2016 | 3466 | 0.450 |
Why?
|
Gonadal Steroid Hormones | 2 | 2021 | 702 | 0.440 |
Why?
|
Middle Aged | 65 | 2024 | 220826 | 0.420 |
Why?
|
Adult | 56 | 2024 | 221148 | 0.420 |
Why?
|
Ovarian Neoplasms | 7 | 2023 | 4876 | 0.410 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2024 | 1520 | 0.410 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2021 | 3514 | 0.380 |
Why?
|
Peptide Fragments | 1 | 2024 | 5115 | 0.380 |
Why?
|
Nitriles | 2 | 2014 | 971 | 0.360 |
Why?
|
Aged | 46 | 2024 | 169235 | 0.360 |
Why?
|
Sarcoma | 1 | 2021 | 1801 | 0.360 |
Why?
|
Triazoles | 2 | 2014 | 903 | 0.350 |
Why?
|
Resistance Training | 3 | 2024 | 193 | 0.350 |
Why?
|
Hormone Antagonists | 1 | 2010 | 107 | 0.350 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2012 | 410 | 0.340 |
Why?
|
Energy Metabolism | 3 | 2023 | 2881 | 0.340 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7389 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2024 | 10203 | 0.320 |
Why?
|
Postmenopause | 4 | 2016 | 2513 | 0.320 |
Why?
|
United States | 22 | 2024 | 72339 | 0.320 |
Why?
|
Health Promotion | 3 | 2016 | 2213 | 0.320 |
Why?
|
Diet, Reducing | 1 | 2012 | 485 | 0.310 |
Why?
|
Leptin | 4 | 2023 | 1597 | 0.310 |
Why?
|
Prognosis | 19 | 2024 | 29620 | 0.310 |
Why?
|
Stress, Psychological | 6 | 2023 | 4477 | 0.310 |
Why?
|
Survival Rate | 7 | 2016 | 12720 | 0.300 |
Why?
|
Complementary Therapies | 2 | 2021 | 486 | 0.280 |
Why?
|
Women's Health | 4 | 2020 | 2065 | 0.280 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 3 | 2010 | 926 | 0.280 |
Why?
|
Epothilones | 2 | 2021 | 42 | 0.280 |
Why?
|
Body Composition | 5 | 2022 | 2422 | 0.280 |
Why?
|
Patient Education as Topic | 3 | 2020 | 2319 | 0.280 |
Why?
|
Taxoids | 3 | 2015 | 667 | 0.270 |
Why?
|
Treatment Outcome | 24 | 2024 | 64651 | 0.270 |
Why?
|
Weight Gain | 4 | 2022 | 2347 | 0.270 |
Why?
|
Republic of Korea | 3 | 2024 | 571 | 0.270 |
Why?
|
Disease-Free Survival | 11 | 2023 | 6814 | 0.270 |
Why?
|
Physicians | 2 | 2023 | 4591 | 0.270 |
Why?
|
Patient Care Team | 1 | 2017 | 2523 | 0.270 |
Why?
|
Feasibility Studies | 6 | 2022 | 5246 | 0.260 |
Why?
|
Muscle Strength | 2 | 2024 | 624 | 0.260 |
Why?
|
Insulin | 5 | 2023 | 6602 | 0.260 |
Why?
|
Colorectal Neoplasms | 5 | 2024 | 6935 | 0.250 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3889 | 0.250 |
Why?
|
Primary Prevention | 3 | 2019 | 1186 | 0.240 |
Why?
|
Dietary Supplements | 1 | 2017 | 3414 | 0.240 |
Why?
|
Androgens | 1 | 2012 | 1286 | 0.240 |
Why?
|
Physician's Role | 3 | 2016 | 916 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4014 | 0.230 |
Why?
|
Cause of Death | 3 | 2024 | 3684 | 0.230 |
Why?
|
Maillard Reaction | 1 | 2023 | 8 | 0.230 |
Why?
|
Societies, Medical | 4 | 2017 | 3905 | 0.220 |
Why?
|
Young Adult | 14 | 2024 | 59207 | 0.220 |
Why?
|
Metabolic Diseases | 1 | 2010 | 681 | 0.220 |
Why?
|
Organizational Objectives | 2 | 2016 | 426 | 0.220 |
Why?
|
Pilot Projects | 6 | 2021 | 8633 | 0.220 |
Why?
|
Nurse Practitioners | 2 | 2024 | 271 | 0.220 |
Why?
|
Bone Density | 2 | 2016 | 3551 | 0.220 |
Why?
|
Brain Neoplasms | 6 | 2024 | 9031 | 0.210 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2024 | 209 | 0.210 |
Why?
|
Vincristine | 1 | 2024 | 1036 | 0.200 |
Why?
|
Adaptation, Psychological | 5 | 2020 | 2632 | 0.200 |
Why?
|
Depression | 8 | 2023 | 8122 | 0.200 |
Why?
|
Hypoglycemic Agents | 7 | 2024 | 3081 | 0.190 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1051 | 0.190 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2021 | 297 | 0.190 |
Why?
|
Male | 26 | 2024 | 360736 | 0.190 |
Why?
|
China | 2 | 2024 | 2366 | 0.180 |
Why?
|
Overweight | 6 | 2022 | 2413 | 0.180 |
Why?
|
Vinblastine | 1 | 2002 | 488 | 0.180 |
Why?
|
Intention | 1 | 2023 | 347 | 0.180 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2020 | 36 | 0.180 |
Why?
|
Integrative Medicine | 1 | 2021 | 87 | 0.180 |
Why?
|
Neoplasm Staging | 11 | 2020 | 11106 | 0.170 |
Why?
|
Risk Factors | 16 | 2020 | 74167 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13337 | 0.170 |
Why?
|
Music | 1 | 2023 | 245 | 0.170 |
Why?
|
Pain, Postoperative | 2 | 2020 | 1737 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39117 | 0.170 |
Why?
|
Osteoprotegerin | 1 | 2020 | 176 | 0.170 |
Why?
|
Pandemics | 4 | 2023 | 8641 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2011 | 2046 | 0.160 |
Why?
|
Nausea | 1 | 2022 | 679 | 0.160 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 551 | 0.160 |
Why?
|
Self Care | 1 | 2024 | 796 | 0.160 |
Why?
|
Vomiting | 1 | 2022 | 652 | 0.160 |
Why?
|
Fertility | 2 | 2023 | 771 | 0.150 |
Why?
|
Endocrine System | 1 | 2019 | 114 | 0.150 |
Why?
|
Interdisciplinary Communication | 2 | 2015 | 931 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 350 | 0.150 |
Why?
|
Biomedical Research | 4 | 2019 | 3429 | 0.150 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 700 | 0.150 |
Why?
|
Prevalence | 3 | 2024 | 15717 | 0.150 |
Why?
|
Range of Motion, Articular | 1 | 2024 | 1586 | 0.150 |
Why?
|
Clinical Trials as Topic | 7 | 2020 | 8000 | 0.150 |
Why?
|
Saliva | 1 | 2022 | 827 | 0.140 |
Why?
|
Mastectomy | 2 | 2024 | 1822 | 0.140 |
Why?
|
Meditation | 1 | 2020 | 251 | 0.140 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2021 | 602 | 0.140 |
Why?
|
Mucin-1 | 1 | 2021 | 540 | 0.140 |
Why?
|
Isoantibodies | 1 | 2000 | 674 | 0.140 |
Why?
|
Decision Making | 3 | 2023 | 3929 | 0.130 |
Why?
|
Referral and Consultation | 2 | 2020 | 3600 | 0.130 |
Why?
|
Vegetables | 1 | 2022 | 1196 | 0.130 |
Why?
|
Disease Management | 3 | 2019 | 2507 | 0.130 |
Why?
|
Tamoxifen | 2 | 2011 | 965 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 474 | 0.130 |
Why?
|
Problem Solving | 1 | 2018 | 441 | 0.130 |
Why?
|
Premenopause | 2 | 2020 | 1039 | 0.130 |
Why?
|
Guidelines as Topic | 3 | 2017 | 1385 | 0.130 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2018 | 591 | 0.130 |
Why?
|
Aged, 80 and over | 11 | 2023 | 58956 | 0.120 |
Why?
|
Lymphedema | 2 | 2019 | 525 | 0.120 |
Why?
|
Blood Glucose | 3 | 2016 | 6391 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2421 | 0.120 |
Why?
|
Adolescent | 8 | 2024 | 88313 | 0.120 |
Why?
|
Survival Analysis | 5 | 2016 | 10089 | 0.120 |
Why?
|
Body Height | 1 | 2021 | 1570 | 0.120 |
Why?
|
Neoplasm Metastasis | 5 | 2024 | 4912 | 0.120 |
Why?
|
Breast | 2 | 2020 | 1966 | 0.120 |
Why?
|
Tai Ji | 1 | 2017 | 289 | 0.110 |
Why?
|
Vitamin B 12 | 1 | 2017 | 524 | 0.110 |
Why?
|
Hydrocortisone | 1 | 2022 | 1815 | 0.110 |
Why?
|
Mastectomy, Segmental | 2 | 2016 | 953 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2977 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1784 | 0.110 |
Why?
|
Adiponectin | 3 | 2023 | 1113 | 0.110 |
Why?
|
Infection Control | 1 | 2021 | 982 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1208 | 0.110 |
Why?
|
Health Policy | 2 | 2016 | 2684 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1474 | 0.100 |
Why?
|
Cyclophosphamide | 2 | 2015 | 2218 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 558 | 0.100 |
Why?
|
Insulin Resistance | 3 | 2023 | 3963 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1410 | 0.100 |
Why?
|
Health Education | 1 | 2019 | 1052 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 3712 | 0.100 |
Why?
|
Patient Care | 1 | 2017 | 621 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1808 | 0.100 |
Why?
|
Income | 1 | 2020 | 1876 | 0.100 |
Why?
|
Doxorubicin | 2 | 2015 | 2224 | 0.100 |
Why?
|
Vaccination | 2 | 2014 | 3381 | 0.090 |
Why?
|
Interleukin-6 | 2 | 2018 | 3207 | 0.090 |
Why?
|
Colonic Neoplasms | 2 | 2013 | 2538 | 0.090 |
Why?
|
Receptors, Progesterone | 3 | 2022 | 1129 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1998 | 0.090 |
Why?
|
Research Design | 3 | 2023 | 6178 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2022 | 2574 | 0.090 |
Why?
|
Attention | 1 | 2021 | 2395 | 0.090 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14599 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 444 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8529 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11458 | 0.090 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2014 | 357 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4852 | 0.090 |
Why?
|
Benzothiazoles | 1 | 2011 | 247 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2025 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2242 | 0.090 |
Why?
|
Prospective Studies | 8 | 2022 | 54415 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1227 | 0.090 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15498 | 0.090 |
Why?
|
Child | 4 | 2023 | 80162 | 0.080 |
Why?
|
Pain | 2 | 2022 | 5071 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3418 | 0.080 |
Why?
|
Self Report | 2 | 2021 | 3724 | 0.080 |
Why?
|
Risk Assessment | 5 | 2019 | 23990 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2914 | 0.080 |
Why?
|
Stroke | 1 | 2011 | 9756 | 0.080 |
Why?
|
Connecticut | 2 | 2021 | 364 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5305 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 992 | 0.080 |
Why?
|
Receptor, Insulin | 1 | 2013 | 835 | 0.080 |
Why?
|
Cohort Studies | 7 | 2020 | 41446 | 0.080 |
Why?
|
Reference Values | 1 | 2016 | 4921 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2018 | 1422 | 0.080 |
Why?
|
Alcohol Drinking | 2 | 2012 | 4027 | 0.080 |
Why?
|
Cardiology | 1 | 2019 | 1667 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 527 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3589 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2928 | 0.070 |
Why?
|
C-Reactive Protein | 4 | 2023 | 3823 | 0.070 |
Why?
|
Disability Evaluation | 1 | 2014 | 1836 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6479 | 0.070 |
Why?
|
Motor Activity | 2 | 2014 | 2711 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3201 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1371 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3490 | 0.070 |
Why?
|
Molecular Weight | 1 | 2009 | 2188 | 0.070 |
Why?
|
Motivation | 2 | 2018 | 2006 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 518 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2017 | 2775 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12456 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 1112 | 0.070 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 6986 | 0.070 |
Why?
|
Communicable Diseases | 1 | 2014 | 875 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22168 | 0.060 |
Why?
|
Anthropometry | 1 | 2010 | 1349 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2015 | 2851 | 0.060 |
Why?
|
Nutritional Status | 2 | 2024 | 1613 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2002 | 9179 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2023 | 12330 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5709 | 0.060 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2008 | 517 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3249 | 0.060 |
Why?
|
Pain Measurement | 1 | 2014 | 3550 | 0.060 |
Why?
|
Inflammation | 2 | 2023 | 10762 | 0.060 |
Why?
|
Smoking | 2 | 2012 | 9052 | 0.060 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 1157 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5146 | 0.060 |
Why?
|
Time Factors | 3 | 2014 | 39975 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10441 | 0.050 |
Why?
|
Research | 1 | 2011 | 1977 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2016 | 416 | 0.050 |
Why?
|
Qualitative Research | 2 | 2024 | 3023 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 10498 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 5840 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26112 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2000 | 5670 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15838 | 0.050 |
Why?
|
Platinum Compounds | 1 | 2002 | 95 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 107 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2548 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2023 | 1931 | 0.050 |
Why?
|
Social Class | 1 | 2010 | 2004 | 0.050 |
Why?
|
Macrophages | 1 | 2016 | 5768 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 80582 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 621 | 0.040 |
Why?
|
Holistic Health | 1 | 2020 | 48 | 0.040 |
Why?
|
NAD | 1 | 2024 | 614 | 0.040 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2644 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2017 | 6339 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3979 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 748 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8469 | 0.040 |
Why?
|
Heart Failure | 1 | 2024 | 11674 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2690 | 0.040 |
Why?
|
Infant | 2 | 2019 | 36205 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9612 | 0.040 |
Why?
|
Length of Stay | 1 | 2013 | 6422 | 0.040 |
Why?
|
Utah | 1 | 2018 | 131 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 42254 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 191 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2002 | 678 | 0.040 |
Why?
|
Primary Health Care | 1 | 2015 | 4686 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11118 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3687 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 5365 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7392 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2120 | 0.040 |
Why?
|
Shoulder Joint | 1 | 2024 | 742 | 0.040 |
Why?
|
Platelet Transfusion | 1 | 2000 | 297 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2024 | 1400 | 0.040 |
Why?
|
Methylmalonic Acid | 1 | 2017 | 49 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 561 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2012 | 857 | 0.040 |
Why?
|
Mammography | 1 | 2008 | 2430 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1667 | 0.030 |
Why?
|
Ideal Body Weight | 1 | 2016 | 27 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1674 | 0.030 |
Why?
|
Incidence | 2 | 2012 | 21341 | 0.030 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2016 | 127 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2003 | 1264 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 588 | 0.030 |
Why?
|
Odds Ratio | 3 | 2015 | 9645 | 0.030 |
Why?
|
Mentors | 1 | 2021 | 660 | 0.030 |
Why?
|
Community Health Centers | 1 | 2019 | 461 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2021 | 880 | 0.030 |
Why?
|
Mice, Obese | 1 | 2016 | 420 | 0.030 |
Why?
|
Fasting | 1 | 2021 | 1602 | 0.030 |
Why?
|
Body Size | 1 | 2017 | 463 | 0.030 |
Why?
|
HLA Antigens | 1 | 2000 | 1371 | 0.030 |
Why?
|
Community Health Services | 1 | 2019 | 656 | 0.030 |
Why?
|
American Heart Association | 1 | 2019 | 1045 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2019 | 836 | 0.030 |
Why?
|
Switzerland | 1 | 2015 | 324 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4016 | 0.030 |
Why?
|
Homocysteine | 1 | 2017 | 638 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2003 | 2179 | 0.030 |
Why?
|
Estradiol | 1 | 2021 | 1937 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 908 | 0.030 |
Why?
|
Occupational Therapy | 1 | 2014 | 139 | 0.030 |
Why?
|
Thinness | 1 | 2016 | 490 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1179 | 0.030 |
Why?
|
Algorithms | 2 | 2024 | 14026 | 0.020 |
Why?
|
Exercise Test | 1 | 2019 | 2129 | 0.020 |
Why?
|
Lipids | 1 | 2023 | 3340 | 0.020 |
Why?
|
Standard of Care | 1 | 2015 | 550 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 540 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 942 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2013 | 12143 | 0.020 |
Why?
|
North America | 1 | 2015 | 1276 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18400 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3810 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2220 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1737 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2019 | 818 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1069 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2523 | 0.020 |
Why?
|
Nurses | 1 | 2020 | 2478 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2013 | 590 | 0.020 |
Why?
|
Methylphenidate | 1 | 2014 | 488 | 0.020 |
Why?
|
Testosterone | 1 | 2021 | 2472 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 273 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3122 | 0.020 |
Why?
|
Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 793 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2875 | 0.020 |
Why?
|
Marital Status | 1 | 2010 | 426 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2760 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2010 | 1626 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1377 | 0.020 |
Why?
|
Colectomy | 1 | 2013 | 688 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 916 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2927 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2218 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1471 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 1176 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1504 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 982 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3249 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10766 | 0.020 |
Why?
|
Palliative Care | 1 | 2020 | 3600 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1027 | 0.010 |
Why?
|
Physical Examination | 1 | 2010 | 1254 | 0.010 |
Why?
|
Glucose | 1 | 2016 | 4347 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5335 | 0.010 |
Why?
|
Remission Induction | 1 | 2009 | 2395 | 0.010 |
Why?
|
Counseling | 1 | 2010 | 1546 | 0.010 |
Why?
|
Educational Status | 1 | 2010 | 2520 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3460 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 7956 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15941 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4354 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14409 | 0.010 |
Why?
|
Mice | 2 | 2018 | 81509 | 0.010 |
Why?
|
Animals | 3 | 2018 | 168441 | 0.010 |
Why?
|
Thrombosis | 1 | 2013 | 2942 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12058 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2826 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13502 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22163 | 0.010 |
Why?
|
Anticoagulants | 1 | 2013 | 4813 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36423 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3357 | 0.010 |
Why?
|
Massachusetts | 1 | 2008 | 8832 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13255 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9469 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23441 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26212 | 0.010 |
Why?
|
Mass Screening | 1 | 2008 | 5428 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15262 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15650 | 0.010 |
Why?
|